Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, SpainClara Mazagatos, Jacobo Mendioroz, Virtudes Gallardo García et al.|Influenza and Other Respiratory Viruses|2024Cited by 25
Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case–control study, Spain, 2023/24 seasonOlivier Núñez, Pello Latasa Zamalloa, Rosa Sancho et al.|Eurosurveillance|2025Cited by 25
Severity of respiratory syncytial virus compared with SARS-CoV-2 and influenza among hospitalised adults ≥65 yearsLorena Vega-Piris, Susana Monge, José Luis Mayordomo et al.|Journal of Infection|2024Cited by 17
Nirsevimab Effectiveness Against Rsv Hospital Admission in Children Under 1 Year of Age: A Spanish Population-Based Case Control StudyOlivier Núñez, Susana Monge, Carmen Olmedo et al.|SSRN Electronic Journal|2024Cited by 4
Author response for "Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain"Clara Mazagatos, The SARI Sentinel Surveillance RSV Study Group, Jacobo Mendioroz et al.|Unknown|2024Cited by 0